Iterum Therapeutics plc Increases Previously Announced Bought Deal Public Offering of Ordinary Shares to $40.0 Million

NEXT STORY
Dassault Systèmes: Horizon Therapeutics plc Expands Medidata Partnership to Further Enhance Clinical Trial Efficiencies and Outcomes
PREV STORY
Revolution Medicines Announces Pricing of Upsized $260.9 Million Public Offering of Common Stock
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Iterum Therapeutics plc Increases Previously Announced Bought Deal Public Offering of Ordinary Shares to $40.0 Million

NEXT STORY
Dassault Systèmes: Horizon Therapeutics plc Expands Medidata Partnership to Further Enhance Clinical Trial Efficiencies and Outcomes
PREV STORY
Revolution Medicines Announces Pricing of Upsized $260.9 Million Public Offering of Common Stock
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Digital Pathology Market to Surpass US$ 9,000 Mn by 2026, Says TMR

Digital Pathology Market: Rise in Installation of Digital Pathology Systems to Boost MarketAlbany, NY, ...

author_avatar
NASDAQ Market News

Drug Discovery Services (Target Selection, Validation, Lead Optimization) Market Report 2020

author_avatar
NASDAQ Market News

Alfasigma USA, Inc. Engages Indegene, Inc. to Expand the Promotion of ZELNORM® to Healthcare Professionals in the United States

author_avatar
NASDAQ Market News